Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: an exploratory study

References

• Albani D, Polito L, Forloni G. 2010. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers Dis 19:11–26
   PubMed Web of Science ®Google Scholar
• Anekonda TS, Reddy PH. 2006. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 96:305–313
   PubMed Web of Science ®Google Scholar
• Avila J, Wandosell F, Hernández F. 2010. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev Neurother 10:703–710
   PubMed Web of Science ®Google Scholar
• Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, Wang Y, et al. 2008. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 3:e2264
   PubMed Web of Science ®Google Scholar
• Basil A, Soulet S, Chaher N, Mérillon JM, Chibane M, Monti JP, Richard T. 2012. Wine polyphenols: potential agents in neuroprotection. Oxid Med Cell Longev 2012:805762
   PubMed Web of Science ®Google Scholar
• Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Karla A, Prabhu VV, et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342
   PubMed Web of Science ®Google Scholar
• Benitez DA, Pozo-Guisado E, Clementi M, Castellón E, Fernandez-Salguero PM. 2007. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway. Br J Cancer 96:1595–1604
   PubMed Web of Science ®Google Scholar
• Bertram L, Tanzi RE. 2008. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 9:768–778
   PubMed Web of Science ®Google Scholar
• Bilb M, Esselmann H, Wiltfang J. 2012. Neurochemical biomarkers in Alzheimer's disease and related disorders. Ther Adv Neurol Disord 5:335–348
   PubMed Web of Science ®Google Scholar
• Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. 2004. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101:2173–2178
   PubMed Web of Science ®Google Scholar
• Cecchinato V, Chiaramonte R, Nizzardo M, Cristofaro B, Basile A, Sharbet GV, Comi P. 2007. Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol 74:1568–1574
   PubMed Web of Science ®Google Scholar
• Counts SE, He B, Nadeem M, Wuu J, Scheff SW, Mufson EJ. 2012. Hippocampal drebrin loss in mild cognitive impairment. Neurodegener Dis 10:216–219
   PubMed Web of Science ®Google Scholar
• Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ. 2006. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol 65:592–601
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Milbrandt J. 2007. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 104:7217–7222
   PubMed Web of Science ®Google Scholar
• Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. 1999. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58:376–388
   PubMed Web of Science ®Google Scholar
• de Oliveira RM, Pais TF, Outeiro TF. 2010. Sirtuins: common targets in aging and in neurodegeneration. Curr Drug Targets 11:1270–1280
   PubMed Web of Science ®Google Scholar
• Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, et al. 2002. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 59:398–407
   PubMed Web of Science ®Google Scholar
• Diomede L, Rigacci S, Romeo M, Stefani M, Salmona M. 2013. Oleuropein aglycone protects transgenic C. elegans strains expressing Aβ42 by reducing plaque load and motor deficit. PLoS One 8:e58893
   PubMed Web of Science ®Google Scholar
• Dun XP, Bandeira de Lima T, Allen J, Geraldo S, Gordon-Weeks P, Chilton JK. 2012. Drebrin controls neuronal migration through the formation and alignment of the leading process. Mol Cell Neurosci 49:341–350
   PubMed Web of Science ®Google Scholar
• Dun XP, Chilton JK. 2010. Control of cell shape and plasticity during development and disease by the actin-binding protein Drebrin. Histol Histopathol 25:533–540
   PubMed Web of Science ®Google Scholar
• Filippi-Chiela EC, Villodre ES, Zamin LL, Lenz G. 2011. Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS One 6:e20849
   PubMed Web of Science ®Google Scholar
• Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, et al. 2006. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24:516–524
   PubMed Web of Science ®Google Scholar
• Geraldo S, Khanzada UK, Parsons M, Chilton JK, Gordon-Weeks PR. 2008. Targeting of the F-actin-binding protein drebrin by the microtubule plus-tip protein EB3 is required for neuritogenesis. Nat Cell Biol 10:1181–1189
   PubMed Web of Science ®Google Scholar
• Guerreiro RJ, Gustafson DR, Hardy J. 2012. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging 33:437–456
   PubMed Web of Science ®Google Scholar
• Han YS, Bastianetto S, Dumont Y, Quirion R. 2006. Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J Pharmacol Exp Ther 318:238–245
   PubMed Web of Science ®Google Scholar
• Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, et al. 2008. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223
   PubMed Web of Science ®Google Scholar
• Hooper C, Killick R, Lovestone S. 2008. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104:1433–1439
   PubMed Web of Science ®Google Scholar
• Howlett DR, Richardson JC. 2009. The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP? Histol Histopathol 24:83–100
   PubMed Web of Science ®Google Scholar
• Jiang WJ. 2008. Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun 373:341–344
   PubMed Web of Science ®Google Scholar
• Joseph JA, Denisova NA, Arendash G, Gordon M, Diamond D, Shukitt-Hale B, Morgan D. 2003. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr Neurosci 6:153–162
   PubMed Web of Science ®Google Scholar
• Julien C, Tremblay C, Bendjelloul F, Phivilay A, Coulombe MA, Emond V, Calon F. 2008. Decreased drebrin mRNA expression in Alzheimer disease: correlation with tau pathology. J Neurosci Res 86:2292–2302
   PubMed Web of Science ®Google Scholar
• Kaeberlein M. 2013. Longevity and aging. F1000Prime Rep 5:5
   PubMedGoogle Scholar
• Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. 2009. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54:111–118
   PubMed Web of Science ®Google Scholar
• Kawas CH. 2006. Diet and the risk of Alzheimer's disease. Ann Neurol 59:877--879
   Google Scholar
• Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, et al. 2007. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26:3169–3179
   PubMed Web of Science ®Google Scholar
• Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. 2006. Therapeutic approaches to Alzheimer's disease. Brain 129:2840–2855
   PubMed Web of Science ®Google Scholar
• Klinge CM, Blankenship KA, Risinger KE, Bhatnagar S, Noisin EL, Sumanasekera WK, Zhao L, et al. 2005. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem 280:7460–7468
   PubMed Web of Science ®Google Scholar
• Kojima N, Shirao T. 2007. Synaptic dysfunction and disruption of postsynaptic drebrin-actin complex: a study of neurological disorders accompanied by cognitive deficits. Neurosci Res 58:1–5
   PubMed Web of Science ®Google Scholar
• Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, et al. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109–1122
   PubMed Web of Science ®Google Scholar
• Leduc V, Jasmin-Bélanger S, Poirier J. 2010. APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol Med 16:469–477
   PubMed Web of Science ®Google Scholar
• Leroy K, Yilmaz Z, Brion JP. 2007. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33:43–55
   PubMed Web of Science ®Google Scholar
• Li F, Gong Q, Dong H, Shi J. 2012. Resveratrol, a neuroprotective supplement for Alzheimer's disease. Curr Pharm Des 18:27–33
   PubMed Web of Science ®Google Scholar
• Lin H, Xiong W, Zhang X, Liu B, Zhang W, Cheng J, Huang H. 2011. Notch-1 activation-dependent p53 restoration contributes to resveratrol-induced apoptosis in glioblastoma cells. Oncol Rep 26:925–930
   PubMed Web of Science ®Google Scholar
• Liu F, Iqbal K, Grundke-Iqbal I, Gong CX. 2002. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett 530:209–214
   PubMed Web of Science ®Google Scholar
• Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, Zhang M, et al. 2013. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 123:224–235
   PubMed Web of Science ®Google Scholar
• Marambaud P, Zhao H, Davies P. 2005. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 280:37377–37382
   PubMed Web of Science ®Google Scholar
• Miyamoto E. 2006. Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus. J Pharmacol 100:433–442
   Google Scholar
• Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, Néri C. 2005. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37:349–350
   PubMed Web of Science ®Google Scholar
• Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF. 1999. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58:1010–1019
   PubMed Web of Science ®Google Scholar
• Poirier J. 2003. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 9:94–101
   PubMed Web of Science ®Google Scholar
• Reixach N, Adamski-Werner SL, Kelly JW, Koziol J, Buxbaum JN. 2006. Cell based screening of inhibitors of transthyretin aggregation. Biochem Biophys Res Commun 348:889–897
   PubMed Web of Science ®Google Scholar
• Ribeiro CA, Saraiva MJ, Cardoso I. 2012. Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide–relevance in Alzheimer's disease. PLoS One 7:e45368
   PubMed Web of Science ®Google Scholar
• Rocha-González HI, Ambriz-Tututi M, Granados-Soto V. 2008. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci Therapeutics 14:234–247
   PubMed Web of Science ®Google Scholar
• Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, et al. 2005. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18:602–617
   PubMed Web of Science ®Google Scholar
• Schreiber G. 2002. The evolution of transthyretin synthesis in the choroid plexus. Clin Chem Lab Med 40:1200–1210
   PubMed Web of Science ®Google Scholar
• Sgarbossa A. 2012. Natural biomolecules and protein aggregation: emerging strategies against amyloidogenesis. Int J Mol Sci 13:17121–17137
   PubMed Web of Science ®Google Scholar
• Shim KS, Lubec G. 2002. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci Lett 324:209–212
   PubMed Web of Science ®Google Scholar
• Sikalidis AK, Stipanuk MH. 2010. Growing rats respond to a sulfur amino acid–deficient diet by phosphorylation of the α subunit of eukaryotic initiation factor 2 heterotrimeric complex and induction of adaptive components of the integrated stress response. J Nutr 140:1080–1085
   PubMed Web of Science ®Google Scholar
• Singh TJ, Haque N, Grundke-Iqbal I, Iqbal K. 1995. Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. FEBS Lett 358:267–272
   PubMed Web of Science ®Google Scholar
• Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, Pilotto A. 2011. Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert Rev Neurother 11:677–708
   PubMed Web of Science ®Google Scholar
• Taubenfeld SM, Mileki MH, Monti B, Alberini CM. 2001. The consolidation of new but not reactivated memory requires hippocampal C/EBPbeta. Nat Neurosci 4:813–818
   PubMed Web of Science ®Google Scholar
• Tsuzuki K, Fukatsu R, Yamaguchi H, Tateno M, Imai K, Fujii N, Yamauchi T. 2000. Transthyretin binds amyloid beta peptides, Abeta1-42 and Abeta1-40 to form complex in the autopsied human kidney -- possible role of transthyretin for abeta sequestration. Neurosci Lett 281:171–174
   PubMed Web of Science ®Google Scholar
• van Marum RJ. 2008. Current and future therapy in Alzheimer's disease. Fundam Clin Pharmacol 22:265–274
   PubMed Web of Science ®Google Scholar
• Wada A. 2009. GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front Biosci 14:1558–1570
   PubMed Web of Science ®Google Scholar
• Wang H, Brown J, Marfin M. 2011. Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 53:130–140
   PubMed Web of Science ®Google Scholar
• Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, Thiyagarajan M, et al. 2006. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J 20:2313–2320
   PubMed Web of Science ®Google Scholar
• Zhang H, Schools GP, Lei T, Wang W, Kimelberg HK, Zhou M. 2008. Resveratrol attenuates early pyramidal neuron excitability impairment and death in acute rat hippocampal slices caused by oxygen-glucose deprivation. Exp Neurol 212:44–52
   PubMed Web of Science ®Google Scholar